Vertex Pharmaceuticals Incorporated (VRTX)
Company Info
| ISIN | US92532F1003 |
|---|---|
| CUSIP | 92532F100 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $126.53B |
|---|---|
| EPS (TTM) | $15.40 |
| PE Ratio | 31.84 |
| PEG Ratio | 0.53 |
| Total Revenue (TTM) | $7.69B |
| Gross Profit (TTM) | $6.66B |
| EBITDA (TTM) | $3.45B |
| Year Range | $340.20 - $498.77 |
| Target Price | $481.41 |
| Short % | 1.59% |
| Short Ratio | 2.99 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Vertex Pharmaceuticals Incorporated, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Vertex Pharmaceuticals Incorporated had a return of 20.98% year-to-date (YTD) and 39.88% in the last 12 months. Over the past 10 years, Vertex Pharmaceuticals Incorporated had an annualized return of 17.86%, outperforming the S&P 500 benchmark which had an annualized return of 10.58%.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 20.98% | 13.20% |
| 1 month | 3.89% | -1.28% |
| 6 months | 14.49% | 10.32% |
| 1 year | 39.88% | 18.23% |
| 5 years (annualized) | 24.22% | 12.31% |
| 10 years (annualized) | 17.86% | 10.58% |
Monthly Returns
The table below presents the monthly returns of VRTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 6.51% | -2.92% | -0.65% | -6.03% | 15.92% | 2.94% | 20.98% | ||||||
| 2023 | 11.88% | -10.15% | 8.54% | 8.14% | -5.04% | 8.76% | 0.12% | -1.14% | -0.17% | 4.13% | -2.02% | 14.68% | 40.90% |
| 2022 | 10.68% | -5.36% | 13.46% | 4.69% | -1.67% | 4.89% | -0.49% | 0.48% | 2.76% | 7.76% | 1.41% | -8.73% | 31.50% |
| 2021 | -3.07% | -7.22% | 1.10% | 1.54% | -4.39% | -3.36% | -0.02% | -0.64% | -9.44% | 1.95% | 1.09% | 17.47% | -7.08% |
| 2020 | 3.70% | -1.33% | 6.21% | 5.57% | 14.63% | 0.82% | -6.31% | 2.62% | -2.51% | -23.43% | 9.31% | 3.77% | 7.94% |
| 2019 | 15.21% | -1.13% | -2.54% | -8.14% | -1.66% | 10.35% | -9.14% | 8.04% | -5.89% | 15.38% | 13.44% | -1.26% | 32.13% |
| 2018 | 11.35% | -0.50% | -1.84% | -6.03% | 0.55% | 10.36% | 2.99% | 5.34% | 4.52% | -12.08% | 6.69% | -8.34% | 10.58% |
| 2017 | 16.56% | 5.53% | 20.67% | 8.18% | 4.48% | 4.26% | 17.81% | 5.74% | -5.29% | -3.82% | -1.33% | 3.86% | 103.42% |
| 2016 | -27.88% | -5.80% | -7.02% | 6.10% | 10.45% | -7.65% | 12.76% | -2.57% | -7.72% | -13.01% | 7.58% | -9.73% | -41.45% |
| 2015 | -7.29% | 8.43% | -1.22% | 4.50% | 4.06% | -3.75% | 9.33% | -5.54% | -18.33% | 19.78% | 3.70% | -2.73% | 5.92% |
| 2014 | 6.38% | 2.30% | -12.54% | -4.27% | 6.74% | 31.03% | -6.09% | 5.24% | 20.03% | 0.29% | 4.65% | 0.78% | 59.89% |
| 2013 | 6.87% | 4.56% | 17.41% | 39.75% | 4.57% | -0.34% | -0.32% | -5.83% | 0.89% | -5.90% | -2.70% | 7.03% | 77.33% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current risk-adjusted rank of VRTX is 90, placing it in the top 10% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Vertex Pharmaceuticals Incorporated (VRTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Vertex Pharmaceuticals Incorporated. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Vertex Pharmaceuticals Incorporated was 91.77%, occurring on Nov 11, 2003. Recovery took 2677 trading sessions.
The current Vertex Pharmaceuticals Incorporated drawdown is 0.74%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -91.77% | Nov 3, 2000 | 757 | Nov 11, 2003 | 2677 | Jul 2, 2014 | 3434 |
| -81.22% | Jul 25, 1991 | 228 | Jun 18, 1992 | 993 | May 23, 1996 | 1221 |
| -70.19% | Feb 25, 1997 | 383 | Aug 31, 1998 | 363 | Feb 8, 2000 | 746 |
| -55.25% | Mar 7, 2000 | 29 | Apr 14, 2000 | 43 | Jun 16, 2000 | 72 |
| -49.1% | Aug 20, 2015 | 340 | Dec 22, 2016 | 142 | Jul 19, 2017 | 482 |
Volatility
Volatility Chart
The current Vertex Pharmaceuticals Incorporated volatility is 3.22%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
P/E Ratio
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Vertex Pharmaceuticals Incorporated.
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |